Format

Send to

Choose Destination
J Hematol Oncol. 2017 Jan 11;10(1):13. doi: 10.1186/s13045-016-0380-0.

Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies.

Author information

1
Biotest AG, Landsteinerstraße 5, 63303, Dreieich, Germany.
2
ImmunoGen Inc., 830 Winter Street, Waltham, 02451-1477, MA, USA.
3
Biotest AG, Landsteinerstraße 5, 63303, Dreieich, Germany. christoph.uherek@biotest.com.

Abstract

Indatuximab ravtansine is a monoclonal antibody-linked cytotoxic agent that specifically targets CD138-expressing cells. Monotherapy has been shown to significantly inhibit multiple myeloma tumour growth in vivo and improve host survival. Here, we show that in most cell lines tested, indatuximab ravtansine acts additively or even synergistically with clinically approved therapies for treatment of multiple myeloma. In addition, in vivo mouse xenograft models confirmed the activity of indatuximab ravtansine in combination with lenalidamide and lenalidomide/dexamethasone. Indatuximab ravtansine may therefore be a suitable combination partner for multiple myeloma, and a clinical study is ongoing.

KEYWORDS:

Drug combination; Indatuximab ravtansine; Multiple myeloma; Pre-clinical; Tumour regression

PMID:
28077160
PMCID:
PMC5225632
DOI:
10.1186/s13045-016-0380-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center